At the same time, anti-CSF-1R can significantly reduce the ratio of MDSCs in tumor-infiltrating immune cells (268) and resulted in greater inhibition of tumor angiogenesis and tumor growth when combined with anti-VEGFR-2 antibodies (269). The gene discussed is CSF1R; the disease is neoplasm.